Characterization of C3 in C3 glomerulopathy

被引:41
|
作者
Sethi, Sanjeev [1 ]
Vrana, Julie A. [1 ]
Fervenza, Fernando C. [2 ]
Theis, Jason D. [1 ]
Sethi, Amit [3 ]
Kurtin, Paul J. [1 ]
Zhang, Yuzhou [4 ,5 ]
Smith, Richard J. H. [4 ,5 ]
机构
[1] Mayo Clin, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Internal Med, Div Nephrol & Hypertens, Rochester, MN USA
[3] Mayo High Sch, Rochester, MN USA
[4] Carver Coll Med, Dept Internal Med, Div Nephrol, Mol Otolaryngol & Renal Res Labs, Iowa City, IA 52242 USA
[5] Carver Coll Med, Dept Pediat, Div Nephrol, Mol Otolaryngol & Renal Res Labs, Iowa City, IA 52242 USA
关键词
C3; glomerulonephritis; glomerulopathy; C3dg; complement; dense deposit disease; HEMOLYTIC-UREMIC SYNDROME; DENSE DEPOSIT DISEASE; MASS-SPECTRAL DATA; ALTERNATIVE PATHWAY; SEQUENCE DATABASES; COMPLEMENT; GLOMERULONEPHRITIS; DYSFUNCTION; PROTEOMICS;
D O I
10.1093/ndt/gfw290
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background: C3 glomerulopathy (C3G) is caused by overactivity of the alternative pathway of complement that results in bright glomerular C3 staining with minimal or no deposition of immunoglobulins on immunofluorescence microscopy. Laser microdissection and mass spectrometry of the two subtypes, C3 glomerulonephritis (C3GN) and dense deposit disease (DDD), have identified C3 as the predominant glomerular complement protein, although lesser amounts of C9, C5, C6, C7 and C8 are detectable. C3 plays a central role in complement activity, with its proteolytic cleavage first generating C3a and C3b, followed by inactivation of C3b generating iC3b (which includes C3a and C3b), which undergoes further breakdown yielding C3c and terminal breakdown fragment C3dg. The composition of C3 breakdown products in C3G is not known. Methods: In this study, we chose six cases each of C3GN and DDD to analyze the composition of C3 deposits. We analyzed the amino acid sequence of C3 spectra detected by mass spectrometry to determine the relative abundance of C3 fragments in C3G. Thus we were able to determine the amino acid sequences mapping to the various C3 activation products including C3dg, C3a (C3a1 and a2), and C3b that are part of C3b/iC3b/C3c. Results: C3dg is the predominant cleavage product detected with the highest amino acid coverage. The remaining amino acids map to C3a (C3a1 and a2) and C3b. Amino acids mapping to C3a and C3f are absent. Taken together, the C3a and C3b amino acids represent iC3b prior to or after C3c cleavage of C3dg. The C3 spectra for both C3GN and DDD are surprisingly similar. Conclusion: The finding of large amounts of C3dg suggests that C3b deposition in the glomerulus is an active process triggered by thioester binding of C3b to the glycocalyx overlying the glomerular endothelial cells and glomerular basement membrane. Regulatory protein-mediated inactivation of C3b results in the generation of iC3b. After additional cleavages, mostly C3dg remains.
引用
收藏
页码:459 / 465
页数:7
相关论文
共 50 条
  • [1] Treating C3 glomerulopathy with eculizumab
    Welte, Thomas
    Arnold, Frederic
    Kappes, Julia
    Seidl, Maximilian
    Haeffner, Karsten
    Bergmann, Carsten
    Walz, Gerd
    Neumann-Haefelin, Elke
    BMC NEPHROLOGY, 2018, 19
  • [2] C3 nephritic factor associated with C3 glomerulopathy in children
    Nicolas, Camille
    Vuiblet, Vincent
    Baudouin, Veronique
    Macher, Marie-Alice
    Vrillon, Isabele
    Biebuyck-Gouge, Nathalie
    Dehennault, Maud
    Gie, Sophie
    Morin, Denis
    Nivet, Hubert
    Nobili, Francois
    Ulinski, Tim
    Ranchin, Bruno
    Marinozzi, Maria Chiarra
    Ngo, Stephanie
    Fremeaux-Bacchi, Veronique
    Pietrement, Christine
    PEDIATRIC NEPHROLOGY, 2014, 29 (01) : 85 - 94
  • [3] Recent insights into C3 glomerulopathy
    Barbour, Thomas D.
    Pickering, Matthew C.
    Cook, H. Terence
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 (07) : 1685 - 1693
  • [4] C3 Glomerulopathy
    Riedl, Magdalena
    Thorner, Paul
    Licht, Christoph
    PEDIATRIC NEPHROLOGY, 2017, 32 (01) : 43 - 57
  • [5] Update on C3 glomerulopathy
    Barbour, Thomas D.
    Ruseva, Marieta M.
    Pickering, Matthew C.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 (05) : 717 - 725
  • [6] Complement inhibition in C3 glomerulopathy
    Nester, Carla M.
    Smith, Richard J. H.
    SEMINARS IN IMMUNOLOGY, 2016, 28 (03) : 241 - 249
  • [7] Diagnosis and treatment of C3 glomerulopathy
    Nester, Caria M.
    Smith, Richard J.
    CLINICAL NEPHROLOGY, 2013, 80 (06) : 395 - 404
  • [8] Acquired and genetic drivers of C3 and C5 convertase dysregulation in C3 glomerulopathy and immunoglobulin-associated MPGN
    Roquigny, Julia
    Meuleman, Marie-Sophie
    El Sissy, Carine
    Martins, Paula Vieira
    Meri, Seppo
    Duval, Anna
    Le Quintrec, Moglie
    Fakhouri, Fadi
    Chauvet, Sophie
    Fremeaux-Bacchi, Veronique
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024,
  • [9] C3 Glomerulopathy: Pathogenesis and Treatment
    Ahmad, Syeda Behjat
    Bomback, Andrew S.
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2020, 27 (02) : 104 - 110
  • [10] Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study
    Welte, Thomas
    Arnold, Frederic
    Westermann, Lukas
    Rottmann, Felix A.
    Hug, Martin J.
    Neumann-Haefelin, Elke
    Ganner, Athina
    BMC NEPHROLOGY, 2023, 24 (01)